Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review.
Saba ZanganehNima GoodarziMohammad DoroudianElaheh MovahedPublished in: Reviews in medical virology (2021)
COVID-19 has spread swiftly throughout the world posing a global health emergency. The significant numbers of deaths attributed to this pandemic have researchers battling to understand this new, dangerous virus. Researchers are looking to find possible treatment regimens and develop effective therapies. This study aims to provide an overview of published scientific information on potential treatments, emphasizing angiotensin-converting enzyme II (ACE2) inhibitors as one of the most important drug targets. SARS-CoV-2 receptor-binding domain (RBD); as a viral attachment or entry inhibitor against SARS-CoV-2, human recombinant soluble ACE2; as a genetically modified soluble form of ACE2 to compete with membrane-bound ACE2, and microRNAs (miRNAs); as a negative regulator of the expression of ACE2/TMPRSS2 to inhibit SARS-CoV2 entry into cells, are the potential therapeutic approaches discussed thoroughly in this article. This review provides the groundwork for the ongoing development of therapeutic agents and effective treatments against SARS-COV-2.
Keyphrases
- sars cov
- angiotensin converting enzyme
- angiotensin ii
- respiratory syndrome coronavirus
- global health
- public health
- emergency department
- induced apoptosis
- healthcare
- coronavirus disease
- poor prognosis
- binding protein
- cell cycle arrest
- transcription factor
- randomized controlled trial
- risk assessment
- cancer therapy
- oxidative stress
- cell death
- systematic review
- dna binding
- drug delivery
- cell free
- pi k akt
- combination therapy